SCHEMBL23313100

SCHEMBL23313100

CN(C)c1ccc2ccc(OC[C@H]3O[C@@H](n4cc(C5CCCC5)c5c(N)ncnc54)[C@H](O)[C@@H]3O)cc2n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 15/20 1.00
▸ PRMT5 O14744 14/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29772289 0.90 METTL3 (0.98) METTL3PRMT5
SCHEMBL25015662 0.90 METTL3 (0.98) METTL3PRMT5
SCHEMBL23273845 0.90 METTL3 (0.98) METTL3PRMT5
SCHEMBL23313940 0.89 METTL3 (1.00) METTL3PRMT5
SCHEMBL23313943 0.88 METTL3 (0.86) METTL3PRMT5
SCHEMBL23313197 0.85 PRMT5 (1.00) METTL3PRMT5
SCHEMBL23313185 0.84 PRMT5 (0.86) METTL3PRMT5
SCHEMBL23313226 0.82 PRMT5 (1.00) METTL3PRMT5
SCHEMBL25016870 0.81 PRMT5 (1.00) METTL3PRMT5
SCHEMBL18571810 0.81 METTL3 (1.00) METTL3PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
WO-2021079196-A2 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2021-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027361-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 METTL3 1/4885PRMT5 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback